Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
Total Valuation
ZyVersa Therapeutics has a market cap or net worth of $1.08M. The enterprise value is $609.90K.
Market Cap$1.08M
Enterprise Value$609.90K
Share Statistics
ZyVersa Therapeutics has 8,095,921 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,095,921
Owned by Insiders6.64%
Owned by Institutions<0.01%
Financial Efficiency
ZyVersa Therapeutics’s return on equity (ROE) is -1.11K and return on invested capital (ROIC) is -97461.45%.
Return on Equity (ROE)-1.11K
Return on Assets (ROA)-456.98
Return on Invested Capital (ROIC)-97461.45%
Return on Capital Employed (ROCE)-975.31
Revenue Per Employee0.00
Profits Per Employee-1.34M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ZyVersa Therapeutics is ―. ZyVersa Therapeutics’s PEG ratio is <0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio0.14
Price to Fair Value0.14
Price to FCF-0.16
Price to Operating Cash Flow>-0.01
PEG Ratio<0.00001
Income Statement
In the last 12 months, ZyVersa Therapeutics had revenue of 0.00 and earned -9.41B in profits. Earnings per share was -8.48.
Revenue0.00
Gross Profit-6.93K
Operating Income-9.14B
Pretax Income-9.42B
Net Income-9.41B
EBITDA-9.14B
Earnings Per Share (EPS)-8.48
Cash Flow
In the last 12 months, operating cash flow was -4.70B and capital expenditures 0.00, giving a free cash flow of -4.70B billion.
Operating Cash Flow-4.70B
Free Cash Flow-4.70B
Free Cash Flow per Share-580.78
Dividends & Yields
ZyVersa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change-88.70%
50-Day Moving Average0.14
200-Day Moving Average0.37
Relative Strength Index (RSI)44.41
Average Volume (3m)51.59K
Important Dates
ZyVersa Therapeutics upcoming earnings date is Apr 1, 2026, Before Open (Confirmed).
Last Earnings DateNov 19, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
ZyVersa Therapeutics as a current ratio of 0.15, with Debt / Equity ratio of 0.00%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio-33.86K
Taxes
In the past 12 months, ZyVersa Therapeutics has paid -6.75M in taxes.
Income Tax-6.75M
Effective Tax Rate<0.01
Enterprise Valuation
ZyVersa Therapeutics EV to EBITDA ratio is <0.01, with an EV/FCF ratio of 0.05.
EV to Sales0.00
EV to EBITDA<0.01
EV to Free Cash Flow0.05
EV to Operating Cash Flow0.05
Balance Sheet
ZyVersa Therapeutics has $527.98K in cash and marketable securities with $0.00 in debt, giving a net cash position of $527.98K billion.
Cash & Marketable Securities$527.98K
Total Debt$0.00
Net Cash$527.98K
Net Cash Per Share$0.07
Tangible Book Value Per Share-$9.13
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ZyVersa Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast88.30%